Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In ...

Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in ...

Finding they were “arbitrary and capricious” under the Administrative Procedures Act, the District Court for the District of Columbia vacated a White House Office of Personnel Management memo and a ...

After delaying a June PDUFA date, the U.S. FDA has approved Kalvista Pharmaceuticals Inc.’s Ekterly (sebetralstat) for hereditary angioedema (HAE) in those aged 12 and older. The plasma kallikrein ...

A recent study published in the Journal for Immunotherapy of Cancer has revealed a promising new approach for the treatment ...

Field Medical Inc. continues to reap funding from investors for its pulsed field ablation (PFA) system with a $35 million ...

The first systematic whole genome sequencing study of how chemotherapy damages healthy tissues has shown that many, but not ...

The oxidase, cytochrome c, assembly 1-like (OXA1L) gene plays a key role in inserting and assembling proteins in the inner ...

Chinese investigators have published data from studies investigating CYT-997 for the treatment of hypertrophic scars. CYT-997 is a tubulin polymerization inhibitor that reached phase II clinical ...

Researchers at Washington University reported the preclinical validation of [18F]FQ-NeuroROS, a redox-sensitive reporter ...

All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, ...

Protagonist Therapeutics Inc. has nominated PN-477 as a development candidate for the treatment of obesity. Copyright ©2025.